Drug Profile
Research programme: anticancer antibodies - BioInvent/InNexus
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator BioInvent International; InNexus Biotechnology
- Class Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Sweden (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 Sep 2006 Early research in Cancer in Sweden (unspecified route)